Immunotherapy targeting programmed cell death 1 (PD‐1) and programmed cell death ligand 1 (PD‐L1) has emerged as a potential therapeutic option for recurrent or metastatic (R/M) HNSCC.1, 2. Here, CD274 is linked to head and neck squamous cell carcinoma.